that means that a patient cohort of 169 people without MSC treatment would have (on average) a total of 2 admissions over that 6 month period. If we take the relative risk reduction of 65% seen in the trial then the absolute saving is 1.3 admissions in a 6 month period. If we multiply it out over say a 5 year period then it could save 13 admissions in the 169 patient group over that time period.
insurance companies would assess the cost of those 13 admissions against the cost of the MSCs x 169 patients. So the numbers aren’t in our favour
And I agree that its certainly possible that there is data or something else that the FDA and/or MSB know that we don’t know or understand.
Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase, page-65
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.015(1.01%) |
Mkt cap ! $1.741B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $16.07M | 10.71M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 69209 | $1.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 53583 | 28 |
View Market Depth
| Last trade - 15.24pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |